Effectiveness of multimodality treatment for autoimmune limbic epilepsy

Divyanshu Dubey, John Konikkara, Pradeep N. Modur, Mark Agostini, Puneet Gupta, Francy Shu, Steven Vernino

Research output: Contribution to journalComment/debate

10 Citations (Scopus)

Abstract

We evaluated the outcome of multimodality treatment in autoimmune limbic epilepsy in 3 consecutive patients (2 male and 1 female; age 33-55 years) presenting with a combination of focal non-convulsive status epilepticus, memory impairment, and psychosis. MRI showed right or bitemporal T2 or FLAIR hyperintensity. Video-EEG showed seizures of right temporo-occipital or bitemporal independent onset. Extensive workup failed to reveal infectious aetiology or an underlying tumour. However, the autoantibody panel was positive for one or more of these antibodies: anti-VGKC, anti-GABAB, anti-VGCC (P/Q, N types), and anti-GAD65. All patients received: (1) conventional antiepileptic drugs including levetiracetam, lacosamide, phenobarbital, lamotrigine, and valproate; (2) immunomodulatory therapy including methylprednisolone, plasmapheresis, and intravenous immunoglobulin; and (3) rituximab. After a 4-6-week in-hospital course, the seizures resolved in all patients but 2 had persistent memory impairment. None had treatment-related complications. At the time of last follow-up, 2-3 months later, 2 patients remained seizure-free while 2 had residual memory impairment. Our findings suggest that multimodality treatment with a combination of conventional AEDs, immunomodulatory therapy, and rituximab is effective and safe in autoimmune limbic epilepsy.

Original languageEnglish (US)
Pages (from-to)494-499
Number of pages6
JournalEpileptic Disorders
Volume16
Issue number4
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Epilepsy
Seizures
etiracetam
Immunomodulation
Plasmapheresis
Status Epilepticus
Intravenous Immunoglobulins
Methylprednisolone
Valproic Acid
Phenobarbital
Psychotic Disorders
Anticonvulsants
Autoantibodies
Electroencephalography
Anti-Idiotypic Antibodies
Therapeutics
Neoplasms
Rituximab

Keywords

  • Autoimmune epilepsy
  • Limbic encephalitis
  • Paraneoplastic syndrome
  • Rituximab
  • Status epilepticus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Dubey, D., Konikkara, J., Modur, P. N., Agostini, M., Gupta, P., Shu, F., & Vernino, S. (2014). Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disorders, 16(4), 494-499. https://doi.org/10.1684/epd.2014.0703

Effectiveness of multimodality treatment for autoimmune limbic epilepsy. / Dubey, Divyanshu; Konikkara, John; Modur, Pradeep N.; Agostini, Mark; Gupta, Puneet; Shu, Francy; Vernino, Steven.

In: Epileptic Disorders, Vol. 16, No. 4, 01.12.2014, p. 494-499.

Research output: Contribution to journalComment/debate

Dubey, D, Konikkara, J, Modur, PN, Agostini, M, Gupta, P, Shu, F & Vernino, S 2014, 'Effectiveness of multimodality treatment for autoimmune limbic epilepsy', Epileptic Disorders, vol. 16, no. 4, pp. 494-499. https://doi.org/10.1684/epd.2014.0703
Dubey, Divyanshu ; Konikkara, John ; Modur, Pradeep N. ; Agostini, Mark ; Gupta, Puneet ; Shu, Francy ; Vernino, Steven. / Effectiveness of multimodality treatment for autoimmune limbic epilepsy. In: Epileptic Disorders. 2014 ; Vol. 16, No. 4. pp. 494-499.
@article{b1912168b61d4d4d9f25ff2365595b69,
title = "Effectiveness of multimodality treatment for autoimmune limbic epilepsy",
abstract = "We evaluated the outcome of multimodality treatment in autoimmune limbic epilepsy in 3 consecutive patients (2 male and 1 female; age 33-55 years) presenting with a combination of focal non-convulsive status epilepticus, memory impairment, and psychosis. MRI showed right or bitemporal T2 or FLAIR hyperintensity. Video-EEG showed seizures of right temporo-occipital or bitemporal independent onset. Extensive workup failed to reveal infectious aetiology or an underlying tumour. However, the autoantibody panel was positive for one or more of these antibodies: anti-VGKC, anti-GABAB, anti-VGCC (P/Q, N types), and anti-GAD65. All patients received: (1) conventional antiepileptic drugs including levetiracetam, lacosamide, phenobarbital, lamotrigine, and valproate; (2) immunomodulatory therapy including methylprednisolone, plasmapheresis, and intravenous immunoglobulin; and (3) rituximab. After a 4-6-week in-hospital course, the seizures resolved in all patients but 2 had persistent memory impairment. None had treatment-related complications. At the time of last follow-up, 2-3 months later, 2 patients remained seizure-free while 2 had residual memory impairment. Our findings suggest that multimodality treatment with a combination of conventional AEDs, immunomodulatory therapy, and rituximab is effective and safe in autoimmune limbic epilepsy.",
keywords = "Autoimmune epilepsy, Limbic encephalitis, Paraneoplastic syndrome, Rituximab, Status epilepticus",
author = "Divyanshu Dubey and John Konikkara and Modur, {Pradeep N.} and Mark Agostini and Puneet Gupta and Francy Shu and Steven Vernino",
year = "2014",
month = "12",
day = "1",
doi = "10.1684/epd.2014.0703",
language = "English (US)",
volume = "16",
pages = "494--499",
journal = "Epileptic Disorders",
issn = "1294-9361",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Effectiveness of multimodality treatment for autoimmune limbic epilepsy

AU - Dubey, Divyanshu

AU - Konikkara, John

AU - Modur, Pradeep N.

AU - Agostini, Mark

AU - Gupta, Puneet

AU - Shu, Francy

AU - Vernino, Steven

PY - 2014/12/1

Y1 - 2014/12/1

N2 - We evaluated the outcome of multimodality treatment in autoimmune limbic epilepsy in 3 consecutive patients (2 male and 1 female; age 33-55 years) presenting with a combination of focal non-convulsive status epilepticus, memory impairment, and psychosis. MRI showed right or bitemporal T2 or FLAIR hyperintensity. Video-EEG showed seizures of right temporo-occipital or bitemporal independent onset. Extensive workup failed to reveal infectious aetiology or an underlying tumour. However, the autoantibody panel was positive for one or more of these antibodies: anti-VGKC, anti-GABAB, anti-VGCC (P/Q, N types), and anti-GAD65. All patients received: (1) conventional antiepileptic drugs including levetiracetam, lacosamide, phenobarbital, lamotrigine, and valproate; (2) immunomodulatory therapy including methylprednisolone, plasmapheresis, and intravenous immunoglobulin; and (3) rituximab. After a 4-6-week in-hospital course, the seizures resolved in all patients but 2 had persistent memory impairment. None had treatment-related complications. At the time of last follow-up, 2-3 months later, 2 patients remained seizure-free while 2 had residual memory impairment. Our findings suggest that multimodality treatment with a combination of conventional AEDs, immunomodulatory therapy, and rituximab is effective and safe in autoimmune limbic epilepsy.

AB - We evaluated the outcome of multimodality treatment in autoimmune limbic epilepsy in 3 consecutive patients (2 male and 1 female; age 33-55 years) presenting with a combination of focal non-convulsive status epilepticus, memory impairment, and psychosis. MRI showed right or bitemporal T2 or FLAIR hyperintensity. Video-EEG showed seizures of right temporo-occipital or bitemporal independent onset. Extensive workup failed to reveal infectious aetiology or an underlying tumour. However, the autoantibody panel was positive for one or more of these antibodies: anti-VGKC, anti-GABAB, anti-VGCC (P/Q, N types), and anti-GAD65. All patients received: (1) conventional antiepileptic drugs including levetiracetam, lacosamide, phenobarbital, lamotrigine, and valproate; (2) immunomodulatory therapy including methylprednisolone, plasmapheresis, and intravenous immunoglobulin; and (3) rituximab. After a 4-6-week in-hospital course, the seizures resolved in all patients but 2 had persistent memory impairment. None had treatment-related complications. At the time of last follow-up, 2-3 months later, 2 patients remained seizure-free while 2 had residual memory impairment. Our findings suggest that multimodality treatment with a combination of conventional AEDs, immunomodulatory therapy, and rituximab is effective and safe in autoimmune limbic epilepsy.

KW - Autoimmune epilepsy

KW - Limbic encephalitis

KW - Paraneoplastic syndrome

KW - Rituximab

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=84920668312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920668312&partnerID=8YFLogxK

U2 - 10.1684/epd.2014.0703

DO - 10.1684/epd.2014.0703

M3 - Comment/debate

C2 - 25465439

AN - SCOPUS:84920668312

VL - 16

SP - 494

EP - 499

JO - Epileptic Disorders

JF - Epileptic Disorders

SN - 1294-9361

IS - 4

ER -